What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
BPC-157 + TB-500 repair-stack blend
Overview
Wolverine Blend is PeptideXpo's pre-blended BPC-157 + TB-500 co-lyophilized vial, the canonical 'repair-stack' combination in the catalog. The two peptides act through complementary mechanisms: BPC-157 (the 15-amino-acid Body Protection Compound) signals through nitric-oxide-pathway modulation and growth-factor-receptor cross-talk, while TB-500 (the 43-amino-acid Thymosin β4 fragment) binds and sequesters actin to drive cellular migration, angiogenesis, and tissue remodeling. The mechanisms are sufficiently distinct that the combination produces additive effects in repair-research models rather than redundant signaling. For the full mechanistic comparison of the two components, see our [BPC-157 vs TB-500 article](/insights/bpc-157-vs-tb-500-side-by-side). PeptideXpo supplies Wolverine Blend as a co-lyophilized lyophilized vial with both components at ≥99.0% HPLC purity each. Standard ratios are 1:1 by mass (the 10 mg vial is 5+5 mg, the 20 mg vial is 10+10 mg) with custom ratios available through OEM service for buyers wanting to bias toward one component. Five fill sizes (10-80 mg total) cover everything from research aliquot work to compounding-pharmacy dispensing scales. The release packet certifies both component purities individually and the actual ratio in the released vial, buyers should always request the verified-ratio number rather than relying on the nominal label.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: 503A / 503B compounding pharmacies, medical aesthetic clinics and med spas, and regional distributors and re-sellers.
Specifications
Documentation available on request
Regulatory note
Sold as a multi-peptide active for research and for OEM-formulated finished products under the receiving brand's regulatory framework. Blend composition, finished-product safety, labeling claims, and notification responsibilities remain with the brand owner. Component-level analytical data is supplied for every batch.
Frequently asked questions
The two peptides act through entirely different molecular mechanisms, BPC-157 modulates nitric-oxide-pathway and growth-factor signaling, while TB-500 sequesters actin and drives cellular migration. They produce additive effects on tissue-repair readouts because the mechanisms are parallel rather than redundant. Combining them in a single co-lyophilized vial simplifies handling and provides a single documentation chain certifying both components and the actual ratio. The convenience matters operationally: most compounding pharmacy and research workflows that use both peptides prefer a single combined product over managing two separate inventories and ensuring consistent ratio in self-mixed preparations.
Custom ratios in the Wolverine Blend are configured per OEM specification. Common variations beyond the standard 1:1 by mass include: **2:1 BPC-heavy** (10 mg BPC-157 + 5 mg TB-500 per vial) for research emphasizing nitric-oxide-pathway and growth-factor-receptor effects with TB-500 as supporting actin-binding signal; **1:2 TB-heavy** (5 mg BPC-157 + 10 mg TB-500 per vial) for research emphasizing cellular-migration and tissue-remodeling effects with BPC-157 as supporting protease-resistant signaling; and **1:1 at larger total mass** (10+10, 15+15, 20+20 mg per vial) for compounding-pharmacy workflows needing larger per-vial mass at the canonical balanced ratio. The OEM service supports all configurations; the released-batch COA always certifies the actual ratio in the released vial against the target.
The released-batch COA for a co-lyophilized blend should report three numbers: (1) the HPLC purity of each component individually (target ≥99.0% per component), (2) the actual ratio of the two components in the released vial measured by quantitative HPLC against reference standards, and (3) the total peptide mass per vial. The ratio measurement is the most operationally important number, without it, the buyer cannot distinguish between a properly-blended vial and one where one component is missing or under-dosed. Standard acceptance tolerance is ±5% of the nominal ratio (e.g., for a 1:1 blend, the actual ratio should fall within 0.95:1.05 to 1.05:0.95). PeptideXpo's COA includes the explicit measured-ratio number with the actual experimental tolerance band.
Related peptides
